RRBP1 and pancreatic neoplasm: For RRBP1-ALK/Raf1 fusion proteins arising in EIMS and pancreatic cancer, selective kinase inhibitors can impair aberrant kinase activity but must be optimized to overcome RRBP1-mediated drug resistance (73,76).